Myriad Genetics, Inc.

NASDAQ:MYGN   3:59:55 PM EDT
18.21
-0.45 (-2.41%)
Other Pre-Announcement

Myriad Genetics Reports Q1 Loss Per Share Of $0.20

Published: 11/09/2020 14:25 GMT
Myriad Genetics Inc (MYGN) - Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-covid-19 Level at End of Quarter.
Q1 Revenue $145.2 Million Versus Refinitiv Ibes Estimate of $135.2 Million.
Myriad Pursuing Strategic Alternatives for Myriad Rbm and Dermatology Business Units.
Qtrly GAAP Loss per Share of $0.20 and Adjusted Loss per Share of $0.15.
Will Not Provide Financial Guidance for Six-month Transition Period Ending Dec.
31, 2020.
Q1 Earnings per Share View $-0.30 -- Refinitiv Ibes Data (analyst estimates).